Hugel America announces U.S. FDA acceptance of biologics license application for letibotulinumtoxinA for injection to treat glabellar (frown) lines

Hugel

15 June 2021 - Prescription Drug User Fee Act target action date of 31 March 2022.

Hugel America today announced that the biologics license application for letibotulinumtoxinA for Injection, to treat moderate to severe glabellar (frown) lines in adult patients has been accepted for review by the U.S. FDA.

Read Hugel press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier